Axcella Health, Inc. is a biotechnology company. It engages in the research and development of treatment for diseases and improve health using endogenous metabolic modulator, or EMM, and compositions.
Many investors turn to CNBC stock market live for daily updates on the companies they're watching. Read on for 15 things to know about the U.S. stock market.
Wall Street Stock Market & Finance report, prediction for the future: You'll find the Axcella Health share forecasts, stock quote and buy / sell signals below.According to present data Axcella Health's AXLA shares and potentially its market environment have been in a bullish cycle in the last 12 months 8 Wall Street analysts have set twelve-month price targets for Axcella Health in the last year. Their average twelve-month price target is $16.13, suggesting a possible upside of 233.9%. Roth Capital has the highest price target set, predicting AXLA will reach $28.00 in the next twelve months. Company profile page for Axcella Health Inc including stock price, company news, press releases, executives, board members, and contact information Detailed statistics for Axcella Health (AXLA) stock, including valuation metrics, financial numbers, share information and more. 2021-03-18 Axcella Health (NASDAQ:AXLA) Intraday Stock Chart Saturday 10 April 2021 Your Recent History LSE. GKP Gulf Keyst.. LSE. QPP Quindell FTSE. UKX FTSE 100 LSE. IOF Iofina FX. GBPUSD UK Sterlin..
Find the latest Axcella Health Inc. (AXLA) stock quote, history, news and other vital information to help you with your stock trading and investing. 2021-03-30 · Axcella Health started at overweight with $20 stock price target at J.P. Morgan Jun. 3, 2019 at 8:30 a.m. ET by Tomi Kilgore Uber in driver’s seat as IPO market gears up for busiest week since 2015 Stock analysis for Axcella Health Inc (AXLA:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. 2021-03-17 · Axcella Health's stock was trading at $3.32 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AXLA stock has increased by 30.7% and is now trading at $4.34. 2021-04-07 · Axcella Health (NASDAQ: AXLA) shares are trading higher on Thursday, after Wedbush initiated coverage on the stock with an Outperform rating and announced a price target of $28 per share. 10 months ago - Benzinga AXLA: Get the latest Axcella Health stock price and detailed information including AXLA news, historical charts and realtime prices.
How much did William Få omedelbar tillgång till detaljerad information om tekniska analyser och handelssignaler för Axcella Health Inc aktien.
Stock analysis for Axcella Health Inc (AXLA:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
Axcella Health stock was originally listed at a price of $13.80 in May 9, 2019 . Description. Axcella Health Inc a biotechnology company involved in the research and development of novel multifactorial interventions to support health and address dysregulated metabolism.
Today, we revisit Axcella Health for the first time in a year. The stock hasn't done much in the 12 months since then but analyst support remains strong.
UKX FTSE 100 LSE. IOF Iofina FX. GBPUSD UK Sterlin.. Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously. Register now to create your 2021-04-01 Axcella stock analysis module also helps to analyze the Axcella Health price relationship with some important fundamental indicators such as market cap and management efficiency. Axcella Stock Analysis Notes. About 17.0% of the company shares are held by company insiders. Axcella Health Inc. operates as a clinical stage biotechnology company in the United States.
Alerte sur rupture; CUMP; Détection des erreurs de stock; Gestion des entrées / sorties; Gestion des fabricants; Référence des produits; Stock minimum /
1 day ago Axcella Health, Inc. (AXLA) balance sheet -- includes annual financial data ( assets, liabilities and equity) for the Shares Outstanding, 37.69B. Axcella Health Inc. sec form 4 filings insider trading, stock buying and selling. " Insiders might sell their shares for any number of reasons, but they buy them for
Salary, bonuses, stock options, stock awards and other compensation for William Hinshaw, President and CEO at Axcella Health Inc..
Skriva uppsats inledning
UKX FTSE 100 LSE. IOF Iofina FX. GBPUSD UK Sterlin.. Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously. Register now to create your 2021-04-01 Axcella stock analysis module also helps to analyze the Axcella Health price relationship with some important fundamental indicators such as market cap and management efficiency. Axcella Stock Analysis Notes.
It engages in the research and development of treatment for diseases and improve health using endogenous metabolic modulator, or EMM, and compositions. The Investor Relations website contains information about Axcella Health Inc.'s business for stockholders, potential investors, and financial analysts. View Axcella Health Inc. AXLA investment & stock information. Get the latest Axcella Health Inc. AXLA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.
Below deck season 8
Detailed statistics for Axcella Health (AXLA) stock, including valuation metrics, financial numbers, share information and more.
The company's lead product candidates include AXA1665 for the treatment of overt hepatic encephalopathy; and AXA1125 for treating non-alcoholic steatohepatitis. AXCELLA HEALTH INC. () : Stock quote, stock chart, quotes, analysis, advice, financials and news for share AXCELLA HEALTH INC. | Nasdaq Other: AXLA | Nasdaq Other 2020-08-13 2020-07-01 Axcella Health Inc. (NASDAQ: AXLA) stock closed at 4.63 per share at the end of the most recent trading day (a -4.14 % change compared to the prior day closing price) with a volume of 63.39K shares and market capitalization of 174.13M.Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 66 people.